Atlas Trials

Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

5 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

RecordFirmDate
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (NCT06393751)National Cancer Institute (NCI)2025-10-31
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NCT05295589)National Cancer Institute (NCI)2022-06-30
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800)National Cancer Institute (NCI)2021-06-10
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT03113487)City of Hope Medical Center2018-02-01
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02839707)National Cancer Institute (NCI)2017-06-23

Track Recurrent Platinum-Resistant Primary Peritoneal Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.